GeoVax Hemorrhagic Fever Vaccine Data Presented at World Vaccine Congress
30. November 2023 16:30 ET
|
GeoVax, Inc.
80% Survival in Nonhuman Primates Observed in a Lethal Challenge Model ATLANTA, GA, Nov. 30, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company...
GeoVax to Participate in Upcoming December Investor Events
29. November 2023 09:00 ET
|
GeoVax, Inc.
ATLANTA, GA, Nov. 29, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious...
GeoVax COVID-19 Vaccine Clinical Data Presented at World Vaccine Congress
28. November 2023 09:00 ET
|
GeoVax, Inc.
Presentation of Data from Phase 2 Open-Label Study of GEO-CM04S1 Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients ATLANTA,...
Progress on GeoVax’s Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023
14. November 2023 09:00 ET
|
GeoVax, Inc.
Single-Dose Protection Demonstrated Against Multiple SARS-CoV-2 Variants ATLANTA, GA, Nov. 14, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company...
GeoVax Reports Third Quarter 2023 Financial Results and Provides Business Update
08. November 2023 16:00 ET
|
GeoVax, Inc.
Significant Progress towards data milestones in Phase 2 Program of GEO-CM04S1, Next-generation COVID-19 vaccine Gedeptin® clinical data from Phase 1/2 study presented at AACR-AHNS Head and Neck...
GeoVax to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 8, 2023
31. Oktober 2023 09:00 ET
|
GeoVax, Inc.
GeoVax to Host Conference Call at 4:30 PM ET ATLANTA, GA, Oct. 31, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing...
GeoVax Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine
30. Oktober 2023 09:00 ET
|
GeoVax, Inc.
Designed to Protect Immunocompromised Patients Against Severe COVID-19 ATLANTA, GA, Oct. 30, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company...
GeoVax to Participate in Upcoming November Investor and Industry Events
25. Oktober 2023 09:00 ET
|
GeoVax, Inc.
ATLANTA, GA, Oct. 25, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious...
GeoVax Update: Clinical and Operational Progress Toward Transformative Opportunities
24. Oktober 2023 09:00 ET
|
GeoVax, Inc.
ATLANTA, GA, Oct. 24, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious...
GeoVax Receives Notice of Allowance for Marburg Vaccine Patent
09. Oktober 2023 09:00 ET
|
GeoVax, Inc.
ATLANTA, GA, Oct. 09, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious...